Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Single dose of esketamine during surgery may ward off Post-Op depression in ovarian cancer patients

NCT ID NCT06624878

Prevention Sponsor: Zhejiang Cancer Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving a low dose of esketamine during ovarian cancer surgery could prevent depressive symptoms that often follow. 568 women undergoing cytoreductive surgery received either esketamine or a placebo. Researchers measured depression using a standard questionnaire three days after surgery. The goal is to find a simple way to protect mental health during a difficult treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
esketamine
What this could lead to
If it works, this could offer a simple way to prevent depression after major cancer surgery, improving mental health and recovery.
What could go wrong
This is a single completed trial with a specific dose and timing. Results may not apply to other surgeries or populations, and the effect may be small or not lasting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

568 people

The number who actually took part.

Started

Oct 2024

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * undergoing cytoreductive surgery for ovarian cancer under general anesthesia * ASA physical status I-III * Ages 18-80 years Exclusion Criteria: * Patients taking anti-psychotic medications * Contraindications to esketamine * Language barrier * Inability to provide consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cytoreductive surgery are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Depression ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cytoreductive surgery Depressive symptom Ovarian cancer

Contacts and locations

Locations

  • Zhejiang cancer hospital

    Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.